Driving Innovation in Drug Delivery: Stevanato Group’s Integrated Solutions for Evolving Patient Needs

At DCAT 2025, Riccardo Butta, President of the Americas at Stevanato Group, discussed key innovations and strategies the company is employing to address the evolving landscape of drug delivery and containment. One of the primary topics highlighted was how advancements in biotechnology and the growing demand for biologics are driving the need for integrated solutions in drug delivery. Butta emphasized the importance of user-friendly devices that enhance patient compliance, especially in the context of the rise in home-based treatments and therapies involving high-viscosity and large-volume drugs. Additionally, he outlined how the company’s comprehensive solutions, including its proprietary platforms like Alina®, Aidaptus®, and Vertiva®, are designed to support a wide range of therapies while offering robust manufacturing capabilities.

Key Takeaways:

• Understand how advancements in biotechnology and the increasing demand for biologics are shaping the future of drug containment and delivery solutions.
• Explore the growing need for user-friendly devices that improve patient compliance, especially for home-based treatments and therapies with complex characteristics.
• Learn about comprehensive solutions, including contract manufacturing and proprietary platforms, that support a wide range of therapies and drive innovation in the drug delivery sector.